AKT1 and triple-negative breast carcinoma: A recent study showed that mTOR inhibitors can extend survival in patients with advanced breast cancer or metaplastic triple-negative breast cancer, indicating that drugs targeting the PI3K/AKT/mTOR pathway may benefit MPBC patients (19).